会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 6. 发明公开
    • 천궁 및 종대황의 혼합 생약 추출물을 함유하는 호흡기 질환의 예방 또는 치료용 조성물
    • 包含用于治疗或预防呼吸道疾病的CNIDII RHIZOMA和UNDULATUM RHUBARB的混合的草药提取物的组合物
    • KR1020120094563A
    • 2012-08-27
    • KR1020110012410
    • 2011-02-11
    • 환인제약 주식회사
    • 조용백강문규정인호허종현김순한이정훈강지윤정경철이제영김슬기
    • A61K36/234A61K36/708A61P11/06A61P11/00
    • A61K36/234A61K36/708
    • PURPOSE: A composition for prevention or treatment of respiratory diseases containing mixed herb extracts of rhei undulati rhizoma and cnidii rhizome are provided to improve 5- lipoxygenase inhibiting activities, airway narrowing inhibiting activities, airway inflammation inhibitory actions and ear edema antiphlogistic actions. CONSTITUTION: A composition for prevention or treatment of respiratory diseases contains the extract, which is manufactured by extracting the mixture of rhei undulati rhizoma and cnidii rhizome using low grade alcohol having 1-4 carbons or 10-95% thereof, as an active ingredient. The extract is refined by ethyl acetate, and dichloromethane or butanol. The herb medicine mixing weight rate of Cnidii Rhizoma to Rhei undulati Rhizoma is 0.1:1-10:1. A health supplement for prevention or treatment of respiratory diseases contains the extract, which is manufactured by extracting the mixture of rhei undulati rhizoma and cnidii rhizome using low grade alcohol having 1-4 carbons or 10-95% thereof, as an active ingredient.
    • 目的:提供一种预防或治疗含有流感嗜酸性粒细胞和枸杞根茎的混合草药提取物的呼吸系统疾病的组合物,以改善5-脂氧合酶抑制活性,气道狭窄抑制活性,气道炎症抑制作用和耳朵水肿消炎作用。 构成:用于预防或治疗呼吸系统疾病的组合物含有提取物,其通过使用具有1-4个碳原子的低级醇或10-95%的作为活性成分提取混合的流质酸和枸杞子来制备。 萃取液用乙酸乙酯,二氯甲烷或丁醇精制。 Cnidii Rhizoma对Rhei undulati Rhizoma的草药混合重量比为0.1:1-10:1。 用于预防或治疗呼吸系统疾病的健康补充剂含有提取物,其通过使用具有1-4个碳原子的低级醇或10-95%的作为活性成分提取混合的流质酸和枸杞子来制备。
    • 8. 发明公开
    • 부플로메딜인산피리독살을 포함하는 서방성 제제 및 이의 제조방법
    • 包含磷酸二氢吡啶磷酸酯的保持组合物及其方法
    • KR1020110086944A
    • 2011-08-02
    • KR1020100006348
    • 2010-01-25
    • 환인제약 주식회사
    • 최명규조용백이재준이동수
    • A61K9/22A61K47/48A61K47/38
    • A61K9/2054A61K9/0053A61K31/455A61K47/38Y10S514/929
    • PURPOSE: A sustained release formulation containing buflomedil pyridoxal phosphate is provided to delay the release rate of buflomedil pyridoxal phosphate. CONSTITUTION: A sustained release formulation for oral formulation contains buflomedil pyridoxal phosphate as a pharmacologically active ingredient, hydroxypropylmethylcellulose as a sustained release carrier, and pharmaceutically useable additives. The additives include diluent, binder, lubricant, and encapsulation. A method for manufacturing the sustained release formulation comprises: a step of mixing buflomedil pyridoxal phosphate or pharmaceutically acceptable salt thereof, hydroxypropylmethylcellulsoe, diluent, and binder; a step of adding magnesium stearate as a lubricant; and a step of pressing and molding in a tablet form.
    • 目的:提供含有丁氟米汀吡哆醛磷酸盐的持续释放制剂,以延缓罂粟碱吡哆醛磷酸盐的释放速率。 构成:用于口服制剂的持续释放制剂含有作为药理活性成分的布氟米特吡哆醛磷酸酯,作为缓释载体的羟丙基甲基纤维素和药学上可用的添加剂。 添加剂包括稀释剂,粘合剂,润滑剂和包封。 制备缓释制剂的方法包括:将罂粟碱吡哆醛磷酸盐或其药学上可接受的盐,羟丙基甲基纤维素,稀释剂和粘合剂混合的步骤; 加入硬脂酸镁作为润滑剂的步骤; 以及片剂形式的压制和成型步骤。